The company announced that the Food and Drug Administration (FDA) has approved Journavx, a twice-daily pill that it described as a "highly selective NaV1.8 pain signal inhibitor for the treatment of ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Eton Pharmaceuticals (ETON – Research Report) today. The company’s shares ...
Suzetrigine (Journavx) is the first non-opioid painkiller to be approved in the US in 20 years. It could help over 80 million ...
Miki Sogi, an analyst from Bernstein, maintained the Hold rating on Takeda Pharmaceutical Co (TKPHF – Research Report). The associated price ...
The US Food and Drug Administration signed off Thursday on the first new type of pain reliever to be approved in more than ...
At the Senate Finance nomination hearing yesterday, he declined to give a yes-or-no answer about Affordable Care Act tax credit rule renewal.
Many Americans support prohibiting commercials for prescription drugs on television. But enacting that ban could be ...
An Iowa pharmacy technician who was allegedly captured on video stealing prescription medications from a customer has agreed ...
The 15 new drugs combined with the 10 drugs in the first batch represent about a third of Medicare Part D spending on prescription drugs, Becerra said. "It is important to remember that for some ...
About 5.3 million people with Medicare prescription drug coverage used these medications from November 2023 through October 2024 at a cost of $41 billion to the government-funded health program ...
These 15 drugs, used by approximately 5.3 million Medicare Part D enrollees between November 2023 and October 2024, accounted for about $41 billion in total gross covered prescription drug costs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback